Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quemliclustat - Arcus Biosciences

Next Previous
Drug Profile

Quemliclustat - Arcus Biosciences

Alternative Names: AB-680; HY-125286; Small molecule CD73 inhibitor - Arcus Biosciences

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action 5-nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma
  • Phase II Cholangiocarcinoma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer
  • Preclinical Malignant-mesothelioma
  • No development reported Cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Adenocarcinoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 23 Jan 2026 Arcus Biosciences plans a phase I trial in healthy volunteers in January 2026 (IV, Infusion) (NCT07364214)
  • 12 Dec 2025 Arcus Biosciences completes enrolment in its phase III PRISM-1 trial for Pancreatic cancer (First line therapy) in the US, Spain, South Korea, Japan, Italy, France, Austria, Australia earlier this year (NCT06608927)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top